Type 2 Diabetes Mellitus
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Type 2 diabetic patients with disease duration10 <= years; (2) Aged 18-75 years old; (3) HbA1c < 10%; (4) BMI < 40kg/m^2; (5) Stable medication for 1 month before enrollment; (6) Voluntarily participated in this study and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Women who are pregnant, breastfeeding, or planning to become pregnant during the study period; (2) Have participated in any clinical trial of an approved or unapproved investigational drug within 30 days before screening; (3) Renal insufficiency (eGFR < 60); (4) Hepatic dysfunction (Child-Pugh class C); (5) Uncontrolled hypertension with myocardial infarction, transient ischemic attack, acute coronary syndrome, clinically diagnosed chronic heart failure (New York Heart Association class II-IV), or hospitalization for heart failure within 60 days before screening; (6) Uncontrolled and potentially unstable diabetic retinopathy or maculopathy; (7) Presence or history of malignancy within 5 years before screening; (8) Prior solid organ transplantation or waiting for solid organ transplantation; (9) The PAR-Q questionnaire was not suitable for exercise as assessed by a professional physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c; | — |
Secondary
| Measure | Time frame |
|---|---|
| 24 hrs TIR;fasting blood glucose;2-hour postprandial hyperglycemia;Changes in the dosage of hypoglycemic drugs;Diabetic Nephropathy;diabetic retinopathy;diabetic neuropathy;The first occurrence of a composite cardiovascular event (including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalization due to angina pectoris);Body Mass Index;Body Weight;waistline;percentage of body fat;blood lipid profile;hepatic function;fatty liver;Metabolomics indicators;Blood Pressure;The usage of antihypertensive drugs; | — |
Countries
China
Contacts
Huashan Hospital Affiliated to Fudan University